18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

Stopped early

Conditions studied: Malignant Neoplasm

In brief

This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system (immunotherapy). PET/CT scans give detailed pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly expressed in activated immune cells, making them light up during PET/CT scans. Doctors also want to know how 18F-clofarabine is distributed throughout the body before and after treatment with immunotherapies.

Key facts

Study ID

NCT02888301

Run by

Jonsson Comprehensive Cancer Center

People needed

12

Starts

2015-06-12

Expected to finish

2018-04-30

Last updated by the study team

2020-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)
• No restrictions based on gender or racial/ethnic background

You may not qualify if…

• Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge

Where it is running

• UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.